Patients aged 60 years and over with previously untreated acute myeloid leukemia were enrolled in a Phase I study combining tipifarnib with standard induction therapy. The regimen consisted of cytarabine 100 mg/m 2
Introduction
Standard induction chemotherapy for acute myeloid leukemia (AML) consists of cytarabine combined with an anthracycline (3 þ 7 regimen). In patients aged 60 years and older, complete response (CR) rates are in the 55% range. [1] [2] [3] Despite intensive consolidation therapy, most patients subsequently relapse, with median CR durations of about 1 year and remission-free survivals of 20% or less. Attempts to alter induction regimens or post-remission strategies with conventional chemotherapy agents have not improved the outcome in these patients. [2] [3] [4] Cytogenetics has been identified as the most important prognostic factor for CR attainment and relapse. Older patients with adverse risk cytogenetics have a CR rate around 30%, with median survival in the range of 6 months and 2-year remissionfree survival of less than 10%. 5, 6 Farnesyltransferase inhibitors (FTIs) constitute a novel class of agents, which interfere with isoprenylation of RAS proteins; these proteins play a role in the growth and proliferation of AML cells. 7 Tipifarnib (R115777) is a selective nonpeptidomimetic FTI that is orally active. This agent is generally well tolerated, with the major toxicities consisting of mild-moderate myelosuppression, nausea, vomiting and diarrhea. The maximum tolerated dose (MTD) in Phase I studies in AML is 600 mg twice daily for 21/28 days. 8 In a Phase II study using this dose in previously untreated elderly and poor risk AML, a CR rate of 15% was reported. 9 The favorable toxicity profile, antileukemic activity and novel mechanism of action of tipifarnib provide an opportunity to use this agent in combination with standard induction therapy. Preclinical studies have shown that FTIs can have additive or synergistic effects on killing of AML cells in vitro when combined with anthracycline agents. 10 However, because of their antiproliferative effects, these agents may potentially interfere with the cytotoxicity of cell cycle-specific agents such as cytarabine.
This Phase I study was developed to determine the toxicity profile and MTD of tipifarnib when combined with standard 3 þ 7 induction for previously untreated AML patients Xage 60 years. The regimen was designed to maximize overlap between tipifarnib and daunorubicin. As the FTIs can cause a G1 arrest, their combination with cytarabine is theoretically inhibitory. For this reason, tipifarnib was not started until day 6 of cytarabine therapy.
Materials and methods

Eligibility criteria
Patients aged 60 years and over with AML were eligible for this study. Any World health Organization (WHO) subtypes 11 except acute promyelocytic leukemia were eligible, including patients with antecedent hematologic disorders and therapyrelated AML. No prior chemotherapy for AML was permitted except hydroxyurea to control circulating blast counts. Other eligibility requirements included ECOG performance status 0-2, serum bilirubin p1.25 Â upper limit of normal, serum AST and ALT p2.0 Â upper limit of normal and serum creatinine o150 mmol/l. Exclusion criteria included left ventricular ejection fraction o50%, central nervous system involvement with leukemia, uncontrolled intercurrent illness and history of allergic reactions to imidazole drugs or other similar compounds to tipifarnib.
All patients signed an informed consent before enrollment. The study was approved by the research ethics board at each institution. Tipifarnib was provided by the National Cancer Institute through the Clinical Trial Evaluative Program (CTEP); the study was conducted through the Princess Margaret Hospital CTEP Consortium.
Treatment regimen
The treatment plan consisted of cytarabine 100 mg/m 2 continuous intravenous (i.v.) infusion daily Â 7 on days 1-7, daunorubicin 60 mg/m 2 i.v. push daily Â 3 on days 6-8 and tipifarnib twice daily Â 10 days on days 6-15. On daunorubicin dosing days, the tipifarnib morning dose was administered approximately 2 h before the daunorubicin dose. Tipifarnib was escalated over four dose levels in successive patient cohorts (200, 300, 400 and 600 mg twice daily). Initially, three patients were enrolled at each dose level. If no dose-limiting toxicity (DLT) was seen, subsequent patients were escalated to the next dose level. If one DLT was seen, another three patients were treated at the same dose level. Because of the inherent toxicity of the underlying chemotherapy regimen, up to two DLTs were permitted at each dose level. If more than two DLTs were seen, this would be considered the MTD; the next lowest dose level would be considered the recommended dose. Once the recommended dose was determined, up to seven more patients would be treated at that dose level (up to a maximum of 10 patients).
Toxicity evaluation
All patients who had started tipifarnib on day 6 were considered evaluable for toxicity. Non-hematologic toxicity was graded according to NCI Common Toxicity Criteria. Any grade III-IV toxicity was considered dose limiting, with the exception of grade III nausea, vomiting or mucositis, which were only considered a DLT if lasting more than 7 days, and grade III electrolyte abnormalities. Because the induction therapy was expected to produce marrow aplasia for 24-28 days, hematologic recovery times (platelets 420 independent of transfusions or absolute neutrophil count (ANC) 0.5 Â 10 9 /l) greater than 40 days were considered dose limiting. Neutropenic infections were not considered dose limiting, unless related to prolonged hematologic recovery or other severe toxicity. Cytogenetic risk groups were classified by MRC criteria as previously described. 5 
Evaluation of response
Bone marrow aspirate þ /À biopsy was performed at days 28-30 or at hematologic recovery. Responses were defined as follows:
Complete remission (CR): o5% blasts in a normocellular bone marrow, ANC 41.0 Â 10 9 /l and platelets 4100 Â 10 9 /l, and no extramedullary disease. Morphologic leukemia-free state (MLFS): o5% blasts in bone marrow and no extramedullary disease, but incomplete count recovery (ANC o1.0 Â 10 9 /l and/or platelets o100 Â 10 9 /l). Partial remission (PR): ANC 41.0 Â 10 9 /l and platelets 4100 Â 10 9 /l, with 5-25% residual bone marrow blasts or blasts o5% but Auer rods present. No response (NR): Not meeting the criteria for CR, MLFS or PR.
Post-remission therapy
Patients achieving CR were eligible to receive one consolidation cycle using the same regimen and doses as in induction therapy, provided all the initial eligibility criteria still applied with respect to organ function. Following completion of this postremission cycle, patients went off study and were eligible to receive further post-remission treatment at the discretion of the treating physician. Patients not achieving CR with one induction cycle were removed from the study.
Supportive care
All induction cycles were administered on an inpatient leukemia unit. Consolidation cycles were administered on either an inpatient or outpatient basis. Double lumen central venous Hickman catheters were inserted in all patients. Allopurinol 300 mg daily was given from days 1-10 during induction, along with i.v. hydration. Anti-emetic prophylaxis with either granisetron 1 mg i.v. daily or ondansetron 8 mg i.v. twice daily was given on days 6-8. Additional antiemetic agents were given as required. Packed red blood cells were transfused to maintain hemoglobin X80 g/l, and platelets were given to maintain the platelet count X10 Â 10 9 /l. Prophylactic and therapeutic antibiotics were administered as per institutional policies. Certain antibiotics (itraconazole, ketoconazole, clarithromycin and erythromycin) were not permitted until the completion of tipifarnib dosing on day 15. Hematopoietic growth factors were not routinely used but granulocyte-colony-stimulating factor was permitted for patients with life-threatening infections or delayed neutrophil recovery (428 days) during induction, and from day 16 on during consolidation.
Results
The baseline patient characteristics are outlined in Table 1 . Of the 24 patients enrolled, 2 developed septic events at days 0 and 5, respectively, and were removed from the study. Because these events occurred before the start of tipifarnib, these patients were not considered evaluable for the study. The remaining 22 patients were started on tipifarnib and were therefore evaluable.
The major induction toxicities, including DLTs, are summarized in Table 2 . The respiratory arrest at dose level I occurred without prior warning at day 12 of induction; the patient was transferred to the intensive care unit, subsequently recovered but did not attain a CR. The Grade III hyperbilirubinemia was transient and did not recur during consolidation. At dose level IV, the neutropenic enterocolitis and diarrhea were both transient and both patients recovered. The supraventricular tachycardia occurred in a patient with a prior history of this and was felt unlikely to have been related to the study intervention. Abbreviations: AML, acute myeloid leukemia; WBC, white blood cell.
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This patient did require temporary monitoring, but recovered with no sequelae. There were no induction DLTs due to delayed hematologic recovery, and no induction deaths. For the patients achieving CR, the median time to ANC X0.5 was 31 days (range 25-36 days), and the median time to platelets 420 was 22 days (range 20-36 days).
Grade I-II toxicities seen in 415% of patients were as follows: nausea/vomiting 15 patients (63%), diarrhea 14 (58%), anorexia 12 (54%), elevated liver enzymes 5 (21%), elevated bilirubin 5 (21%), elevated creatinine 5 (21%), hyperglycemia 4 (17%), rash 4 (17%) and hypoalbuminemia 4 (17%). Grade I-III electrolyte abnormalities were seen in 19 patients (79%).
The responses to treatment according to dose level are summarized in Table 3 , and the responses according to cytogenetic risk group are shown in Table 4 . Of the 10 patients achieving CR, one did not receive consolidation on study due to a drop in the left ventricular ejection fraction from 74 to 60% (Grade I), this patient received alternate consolidation off study with no sequelae. The remaining nine patients received consolidation on study. One patient (at dose level IV) had prolonged hematologic recovery during consolidation (46 days for both neutrophils and platelets). The median time to ANC X0.5 post-consolidation was 33 days (range 23-46 days), and the median time to platelets 420 was 27 days (range 17-46 days). There were no non-hematologic DLTs during consolidation.
Of the 10 patients achieving CR, 7 have relapsed at a median of 17 months (range 7-26 months). The other three patients remain in continuous CR at 13, 17 and 29 months, respectively.
Discussion
This study shows the feasibility of combining tipifarnib with standard induction chemotherapy in previously untreated AML patients aged 60 years and over. Although toxicities were seen, these were not substantially more than would be expected with 3 þ 7 chemotherapy alone. There was somewhat more severe gastrointestinal toxicity seen at dose level IV (one grade III diarrhea and one neutropenic enterocolitis). This is not surprising as diarrhea is seen at this dose when tipifarnib is used as a single agent. However, this toxicity was not considered dose limiting, and the overall frequency of gastrointestinal toxicity was not greater at higher dose levels.
Myelosuppression is another common toxicity of tipifarnib. Although there were no cases of prolonged hematologic recovery with induction, the median neutrophil recovery time was 2-6 days longer than reported in the literature for patients in this age group not receiving hematopoietic growth factors. 3, 12, 13 The significance of this is unclear, as there was no apparent increase in infectious complications. On the other hand, platelet recovery times were similar to those reported in the literature. Although there was one delayed recovery post-consolidation, median hematologic recovery times were only slightly longer than those seen with the induction course. Although this delayed recovery occurred in a patient treated at dose level IV, there was no apparent trend toward longer recovery times at higher dose levels.
The MTD was not reached during this study. Further tipifarnib dose escalation, either as an increased daily dose or increased dose duration, would be possible. However, given the underlying toxicity of the chemotherapy and the elderly population in this study, it was decided not to proceed with further dose escalation. Nevertheless, this could be considered in future studies, particularly in younger patients.
It is difficult to determine whether there was any increased antileukemic activity with this regimen, as the numbers were small, the study population was heterogeneous with respect to prognostic factors and the tipifarnib doses were variable. The CR/MLFS rate in all patients (55%) and in patients with standard risk cytogenetics (8/14, 57%) was not substantially different than would be expected with chemotherapy alone. However, second inductions were not permitted; it is possible that the two PR patients might have attained CR with a second induction. The CR/MLFS rate in patients with adverse risk cytogenetics (4/ 7, 57%) was higher than the expected response rate of around 30% with standard induction therapy. This needs to be interpreted with caution, as the numbers were very small. However, response rates to tipifarnib as a single agent appear to be independent of cytogenetic risk group. 9 The CR rate seen in this poor prognosis group suggests that this target population would be of particular interest in further studies in a Phase II setting.
Recent studies have questioned the benefit of tipifarnib in AML. A Phase III randomized trial in patients aged 70 years and over did not show a survival advantage as compared with supportive care alone; the CR rate in that study was only 8%. 14 A Phase II study using this agent in combination with idarubicin and high-dose cytarabine in previously untreated AML yielded response rates and survivals that were not different than historical controls. 15 However, in that study the tipifarnib dose was 300 mg twice daily, substantially less than the MTD in this study. On the other hand, a recent report found no apparent increase in response rate with higher tipifarnib doses when used as a single agent, 16 so the benefit of further dose escalation is unclear. Of greater concern, tipifarnib was given concurrently with cytarabine in that study; as indicated earlier, FTIs may inhibit cytarabine-induced cytotoxicity and should probably not be used concurrently with cell cycle-specific agents due to their antiproliferative effects.
In summary, tipifarnib can be safely administered at a dose of 600 mg twice daily for 10 days in combination with standard induction therapy in older AML patients who are judged to be medically fit for such therapy. Further studies are warranted to evaluate the antileukemic activity of this regimen, particularly in patients with adverse risk cytogenetics and other poor risk features.
